Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > Excellent result from Johnson & Johnson

<< Previous

Bullboard Posts

Next >>

Post by fossi_2002on Jul 21, 2023 4:46am

231 Views

Post# 35550998

Excellent result from Johnson & Johnson

Excellent result from Johnson & Johnson. Consumer Health increased sales by 7.7% over the previous year.
"Additional growth momentum came from NEUTROGENA in Skin Health/Beauty Products and Women's Health Products outside the United States. "

This gives us hope that our base business will stabilize in the coming months.
In addition, the outlook for the rest of the year has been adjusted upward.

FULL-YEAR 2023 GUIDANCE:

($ in Billions, except EPS)	July 2023	April 2023
Adjusted Operational Sales^1,2,5 Change vs. Prior Year / Mid-point	6.0% – 7.0% / 6.5%	4.5% – 5.5% / 5.0%
Operational Sales^2,5/ Mid-point Change vs. Prior Year / Mid-point	$99.3B – $100.3B / $99.8B 7.0% – 8.0% / 7.5%	$97.9B – $98.9B / $98.4B 5.5% – 6.5% / 6.0%
Estimated Reported Sales^3,5/ Mid-point Change vs. Prior Year / Mid-point	$98.8B – $99.8B / $99.3B 6.5% – 7.5% / 7.0%	$97.9B – $98.9B / $98.4B 5.5% – 6.5% / 6.0%

Adjusted Operational EPS (Diluted)^2,4/ Mid-point Change vs. Prior Year / Mid-point	$10.60 – $10.70 / $10.65 4.5% – 5.5% / 5.0%	$10.50 – $10.60 / $10.55 3.5% – 4.5% / 4.0%
Adjusted EPS (Diluted)^3,4/ Mid-point Change vs. Prior Year / Mid-point	$10.70 – $10.80 / $10.75 5.5% – 6.5% / 6.0%	$10.60 – $10.70 / $10.65 4.5% – 5.5% / 5.0%